Five Trendlines Portfolio Companies Awarded Total ~€ 8 Million in Horizon 2020 Grants

An agtech, a cleantech and three medical device companies are among the 2018-2019 awardees

Misgav, Israel – 18 June 2019 – The Trendlines Group (The Trendlines Group Ltd. ("**Trendlines**") (SGX: 42T; OTCQX: TRNLY), announced today that during 2018 and the first six months of 2019 five of its portfolio companies were chosen to receive prestigious Horizon 2020 grants.

Horizon 2020 is "the biggest EU Research and Innovation programme ever with nearly €80 billion of funding available over 7 years (2014 to 2020) – in addition to the private investment that this money will attract. It promises more breakthroughs, discoveries and world-firsts by taking great ideas from the lab to the market." Only a small percentage of applicants receive grants for "world-class science," company leadership, and solutions that "tackle societal challenges." According to an EU study released in December, 2017, only 12.6% of applications were approved in the program's first three years.[1]

Through the program, Israeli researchers, start-ups, and innovators have gained access to European partners and the extensive European research infrastructure.

These Trendlines portfolio companies received Horizon 2020 grants, each exceeding € 1 million:

- Saturas Ltd. developed an Advanced Decision Support System (ADSS) for precision irrigation based on its miniature Stem Water Potential (SWP) sensor.
- GreenSpense Ltd. developed a gas-free, high-pressure continuous dispensing solution based on breakthroughs in elastomer technology and materials engineering.
- ElastiMed Ltd. developed a device using smart material-based technology mimicking rhythmic calf muscle contractions to improve circulation.
- ProArc Medical Ltd. developed the ClearRing solution intended to treat symptoms due to urinary outflow obstruction caused by enlarged prostate also known as BPH (Benign Prostatic Hyperplasia).
- liberDi Ltd. developed an all-in-one portable dialysis device providing scalable digital and safe self-care anywhere.

Trendlines Chairman and CEO Steve Rhodes commented, "We're extremely proud of the companies that received non-dilutive funding grants through Horizon 2020 indicating a strong endorsement of their technological progress and promise. The grants affirm the companies'

[1] HORIZON 2020 in full swing: Three years on (https://ec.europa.eu/programmes/horizon2020/sites/horizon2020/files/h2020_threeyearson_a4_horizontal_2018_web.pdf)

excellence and innovation in their respective fields and provide funding to assist them in bringing their technologies to market."

About The Trendlines Group Ltd.

Trendlines is an innovation commercialization company that invents, discovers, invests in, and incubates innovation-based medical and agricultural technologies to fulfill its mission to improve the human condition. As intensely hands-on investors, Trendlines is involved in all aspects of its portfolio companies from technology development to business building. Trendlines' shares are traded on the Singapore Stock Exchange (SGX: 42T) and in the United States as an American Depositary Receipt (ADR) on the OTCQX (OTCQX: TRNLY).

Investor Contact Information
Israel:
Shira Zimmerman, The Trendlines Group
shira@trendlines.com
Tel: +972.72.260.7000

Singapore and China:
Reyna MEI, Financial PR
reyna@financialpr.com.sg
Tel: +65.6438.2990

This press release has been prepared by the Company and its contents have been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. (the "Sponsor") in accordance with Rules 226(2)(b) and 753(2) of the Singapore Exchange Securities Trading Limited (the "SGX-ST") Listing Manual Section B: Rules of Catalist.

This press release has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this press release, including the correctness of any of the statements or opinions made or reports contained in this press release.

The contact person for the Sponsor is Ms. Jennifer Tan, Associate Director, Continuing Sponsorship (Mailing Address: 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318 and E-mail: sponsorship@ppcf.com.sg).